Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1975 2
1979 1
1981 2
1983 4
1984 3
1985 6
1986 7
1987 6
1988 10
1989 12
1990 27
1991 14
1992 17
1993 19
1994 22
1995 18
1996 15
1997 19
1998 16
1999 6
2000 21
2001 12
2002 15
2003 10
2004 16
2005 15
2006 9
2007 15
2008 14
2009 10
2010 16
2011 10
2012 19
2013 20
2014 17
2015 27
2016 20
2017 19
2018 17
2019 6
2020 3
Text availability
Article attribute
Article type
Publication date

Search Results

506 results
Results by year

Citations

1 article found by citation matching

Search results

Filters applied: . Clear all
Page 1
Monocyte function in patients with myelodysplastic syndrome.
Pollyea DA, Hedin BR, O'Connor BP, Alper S. Pollyea DA, et al. J Leukoc Biol. 2018 Sep;104(3):641-647. doi: 10.1002/JLB.5AB1017-419RR. Epub 2018 Apr 14. J Leukoc Biol. 2018. PMID: 29656609 Free PMC article.
Monocytes are also integral to immunologic defense; however, much less is known about monocyte function in patients with MDS. ...We also find that the range of immune functions in monocytes from MDS patients correlates with several
Monocytes are also integral to immunologic defense; however, much less is known about monocyte function in patients
Germline GATA2 Mutation and Bone Marrow Failure.
McReynolds LJ, Calvo KR, Holland SM. McReynolds LJ, et al. Hematol Oncol Clin North Am. 2018 Aug;32(4):713-728. doi: 10.1016/j.hoc.2018.04.004. Epub 2018 May 28. Hematol Oncol Clin North Am. 2018. PMID: 30047422 Free PMC article. Review.
Patients commonly have B-cell, dendritic cell, natural killer cell, and monocytopenias, and are predisposed to myelodysplastic syndrome, acute myeloid leukemia, and chronic myelomonocytic leukemia. Patients may suffer from disseminated human papilloma
Patients commonly have B-cell, dendritic cell, natural killer cell, and monocytopenias, and are predisposed to myelodysplastic
How I treat chronic myelomonocytic leukemia.
Solary E, Itzykson R. Solary E, et al. Blood. 2017 Jul 13;130(2):126-136. doi: 10.1182/blood-2017-04-736421. Epub 2017 Jun 1. Blood. 2017. PMID: 28572287 Review.
In the absence of poor prognostic factors, the management of myelodysplastic CMML is largely inspired from myelodysplastic syndromes, relying on erythropoiesis-stimulating agents to cope with anemia, and careful monitoring and supportive care, whereas the man …
In the absence of poor prognostic factors, the management of myelodysplastic CMML is largely inspired from myelodysplastic
Factors Involved in Maintaining Haemostasis in Patients with Myelodysplastic Syndrome.
Fernández Bello I, Jiménez-Yuste V, de Paz R, Martín Salces M, Justo Sanz R, Monzón Manzano E, Arias-Salgado EG, Álvarez Román MT, Rivas Pollmar MI, Goyanes I, Butta NV. Fernández Bello I, et al. Thromb Haemost. 2018 Apr;118(4):734-744. doi: 10.1055/s-0038-1637733. Epub 2018 Mar 19. Thromb Haemost. 2018. PMID: 29554698 Clinical Trial.
Etiopathogenesis of myelodysplastic syndrome (MDS) might cause per se an anomalous haemostasis that can be even more deteriorated by thrombocytopaenia. ...This factor/s might be antibodies as this effect was observed in samples from MDS patients with a …
Etiopathogenesis of myelodysplastic syndrome (MDS) might cause per se an anomalous haemostasis that can be even more deteriora …
Monocyte-Derived Macrophages Are Impaired in Myelodysplastic Syndrome.
Han Y, Wang H, Shao Z. Han Y, et al. J Immunol Res. 2016;2016:5479013. doi: 10.1155/2016/5479013. Epub 2016 Dec 15. J Immunol Res. 2016. PMID: 28074192 Free PMC article.
Compared with normal control group, the number of monocytes increased in MDS patients. However, the monocytes showed impaired ability to induce macrophages and the number of macrophages induced from MDS samples was lower. ...Monocyte-derived macrophage …
Compared with normal control group, the number of monocytes increased in MDS patients. However, the monocytes showed im …
GATA2 deficiency: a protean disorder of hematopoiesis, lymphatics, and immunity.
Spinner MA, Sanchez LA, Hsu AP, Shaw PA, Zerbe CS, Calvo KR, Arthur DC, Gu W, Gould CM, Brewer CC, Cowen EW, Freeman AF, Olivier KN, Uzel G, Zelazny AM, Daub JR, Spalding CD, Claypool RJ, Giri NK, Alter BP, Mace EM, Orange JS, Cuellar-Rodriguez J, Hickstein DD, Holland SM. Spinner MA, et al. Blood. 2014 Feb 6;123(6):809-21. doi: 10.1182/blood-2013-07-515528. Epub 2013 Nov 13. Blood. 2014. PMID: 24227816 Free PMC article.
Haploinsufficiency of the hematopoietic transcription factor GATA2 underlies monocytopenia and mycobacterial infections; dendritic cell, monocyte, B, and natural killer (NK) lymphoid deficiency; familial myelodysplastic syndromes (MDS)/acute myeloid leukemia …
Haploinsufficiency of the hematopoietic transcription factor GATA2 underlies monocytopenia and mycobacterial infections; dendritic cell, …
Reclassification of Acute Myeloid Leukemia According to the 2016 WHO Classification.
Jung J, Cho BS, Kim HJ, Han E, Jang W, Han K, Lee JW, Chung NG, Cho B, Kim M, Kim Y. Jung J, et al. Ann Lab Med. 2019 May;39(3):311-316. doi: 10.3343/alm.2019.39.3.311. Ann Lab Med. 2019. PMID: 30623623 Free PMC article. Review.
Nine patients were categorized as having myelodysplastic syndrome and myeloid neoplasms with germline predisposition. AML with recurrent genetic abnormalities accounted for 57.4% (345/601) of the patients under the 2016 WHO classification. AML with mut …
Nine patients were categorized as having myelodysplastic syndrome and myeloid neoplasms with germline predisposition. A …
Vitamin K antagonism impairs the bone marrow microenvironment and hematopoiesis.
Verma D, Kumar R, Pereira RS, Karantanou C, Zanetti C, Minciacchi VR, Fulzele K, Kunz K, Hoelper S, Zia-Chahabi S, Jabagi MJ, Emmerich J, Dray-Spira R, Kuhlee F, Hackmann K, Schroeck E, Wenzel P, Müller S, Filmann N, Fontenay M, Pajevic PD, Krause DS. Verma D, et al. Blood. 2019 Jul 18;134(3):227-238. doi: 10.1182/blood.2018874214. Epub 2019 Apr 19. Blood. 2019. PMID: 31003999
Using various transplantation and in vitro assays, we show here that VKAs alter parameters of bone physiology and reduce functional HSCs 8-fold. ...Following published examples that alteration of the BMM can lead to hematological malignancies in mice, we describe, w …
Using various transplantation and in vitro assays, we show here that VKAs alter parameters of bone physiology and reduce functiona
Genome-wide miRNA profiling in myelodysplastic syndrome with del(5q) treated with lenalidomide.
Merkerova MD, Krejcik Z, Belickova M, Hrustincova A, Klema J, Stara E, Zemanova Z, Michalova K, Cermak J, Jonasova A. Merkerova MD, et al. Eur J Haematol. 2015 Jul;95(1):35-43. doi: 10.1111/ejh.12458. Epub 2014 Nov 11. Eur J Haematol. 2015. PMID: 25287904 Free article.
OBJECTIVES: Lenalidomide is a potent drug with pleiotropic effects in patients with myelodysplastic syndrome (MDS) with deletion of the long arm of chromosome 5 [del(5q)]. We investigated its effect on regulation of microRNA (miRNA) expression profiles in del …
OBJECTIVES: Lenalidomide is a potent drug with pleiotropic effects in patients with myelodysplastic syndrome (MDS) with …
GATA2 deficiency and related myeloid neoplasms.
Wlodarski MW, Collin M, Horwitz MS. Wlodarski MW, et al. Semin Hematol. 2017 Apr;54(2):81-86. doi: 10.1053/j.seminhematol.2017.05.002. Epub 2017 May 10. Semin Hematol. 2017. PMID: 28637621 Free PMC article.
During the past 5 years, germline heterozygous mutations in GATA2 were reported in several hundred patients with various phenotypes ranging from mild cytopenia to severe immunodeficiency involving B cells, natural killer cells, CD4(+) cells, monocytes and dendritic …
During the past 5 years, germline heterozygous mutations in GATA2 were reported in several hundred patients with various phenotypes r …
506 results
Jump to page
Feedback